首页> 外文期刊>中华医学杂志(英文版) >Microvolt T-wave alternans complemented with electrophysiologic study for prediction of ventricular tachyarrhythmias in patients with arrhythmogenic right ventricular cardiomyopathy: a long-term follow-up study
【24h】

Microvolt T-wave alternans complemented with electrophysiologic study for prediction of ventricular tachyarrhythmias in patients with arrhythmogenic right ventricular cardiomyopathy: a long-term follow-up study

机译:微伏特T波交替蛋白与电生理研究的结合,用于预测致心律失常性右室心肌病患者的室性心律失常:一项长期随访研究

获取原文
获取原文并翻译 | 示例
           

摘要

Background:The long-term predicted value of microvolt T-wave alternans (MTWA) for ventricular tachyarrhythmia in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) remains unclear.Our study explored the characteristics of MTWA and its prognostic value when combined with an electrophysiologic study (EPS) in patients with ARVC.Methods:All patients underwent non-invasive MTWA examination with modified moving average (MMA) analysis and an EPS.A positive event was defined as the first occurrence of sudden cardiac death,documented sustained ventricular tachycardia (VT),ventricular fibrillation,or the administration of appropriate implantable cardioverter defibrillator therapy including shock or antitachycardia pacing.Results:Thirty-five patients with ARVC (age 38.6 ± 11.0 years;28 males) with preserved left ventricular (LV) function were recruited.The maximal TWA value (MaxValt) was 17.0 (11.0-27.0) μV.Sustained VT was induced in 22 patients by the EPS.During a median follow-up of 99.9 ± 7.7 months,15 patients had positive clinical events.When inducible VT was combined with the MaxValt,the area under the curve improved from 0.739 to 0.797.The receiver operating characteristic curve showed that a MaxValt of 23.5 μV was the optimal cutoff value to identify positive events.The multivariate Cox regression model for survival showed that MTWA (MaxValt,hazard ratio [HR],1.06;95% confidence interval [CI],1.01-1.11;P =0.01) and inducible VT (HR,5.98;95% CI,1.33-26.8;P =0.01) independently predicted positive events in patients with ARVC.Conclusions:MTWA assessment with MMA analysis complemented by an EPS might provide improved prognostic ability in patients with ARVC with preserved LV function during long-term follow-up.
机译:背景:微伏特T波交替蛋白(MTWA)对心律失常性右室心肌病(ARVC)患者室速的长期预测价值尚不清楚。我们的研究探讨了MTWA的特征及其与电生理学结合的预后价值方法:所有患者均接受非侵入性MTWA检查,并进行改良移动平均(MMA)分析和EPS。阳性事件被定义为首次发生心源性猝死,有记录的持续性室性心动过速(VT) ),心室纤颤或采用适当的植入式心脏复律除颤器治疗,包括休克或心动过速起搏。结果:招募了35例ARVC(年龄38.6±11.0岁; 28例男性),其左心室(LV)功能保持正常。最大TWA值(MaxValt)为17.0(11.0-27.0)μV.EPS诱发22例患者持续室速。随访99.9±7.7个月,有15例患者发生了积极的临床事件。当诱导型VT与MaxValt联合使用时,曲线下面积从0.739增至0.797。接收器工作特性曲线显示最大ValVal为23.5μV生存的多元Cox回归模型显示MTWA(MaxValt,危险比[HR],1.06; 95%置信区间[CI],1.01-1.11; P = 0.01)和诱导性VT(HR ,5.98; 95%CI,1.33-26.8; P = 0.01)独立预测ARVC患者的阳性事件。结论:MTWA结合MMA分析和EPS评估可改善ARVC患者长期保持LV功能的预后能力长期随访。

著录项

  • 来源
    《中华医学杂志(英文版)》 |2019年第12期|1406-1413|共8页
  • 作者单位

    Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China;

    Department of Cardiology, The Affiliated Wujin Hospital of Jiangsu University, Changzhou, Jiangsu 213002, China;

    Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China;

    Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China;

    Key Laboratory of Targeted Intervention in Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, Nanjing Medical University,Nanjing, Jiangsu 211166, China;

    Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China;

    Department of Cardiology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, Jiangsu 215008, China;

    Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China;

    Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China;

    Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China;

    Department of Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211166, China;

    Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China;

    Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China;

  • 收录信息 中国科学引文数据库(CSCD);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号